Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population
This study will focus on participants in the United Kingdom (UK) to collect local data on the effectiveness and safety of bevacizumab (Avastin) in the treatment of metastatic colorectal cancer in normal clinical use.
Metastatic Colorectal Cancer
OTHER: No intervention
Overall Survival (OS), From date of metastatic colorectal cancer diagnosis to date of death up to 3 years
Response Rate (RR), From date of metastatic colorectal cancer diagnosis to end of study up to 3 years|Progression Free Survival (PFS), From date of metastatic colorectal cancer diagnosis to end of study up to 3 years|Percentage of Participants with Adverse Events of Special Interest, From date of metastatic colorectal cancer diagnosis to end of study up to 3 years
This study will focus on participants in the United Kingdom (UK) to collect local data on the effectiveness and safety of bevacizumab (Avastin) in the treatment of metastatic colorectal cancer in normal clinical use.